Loader

Pathways

PathWhiz ID Pathway Meta Data

PW128624

Pw128624 View Pathway
drug action

Sibutramine Dopamine Reuptake Inhibitor Action Pathway

Homo sapiens
Sibutramine, commonly known as Meridia or Reductil, is a norepinephrine, serotonin and dopamine reuptake inhibitor used for the treatment of obesity. This drug was withdrawn from US and Canadian markets for increased risk of heart attack and stroke in patients with heart disease history. Sibutramine stimulates the nervous system through the reuptake of norepinephrine, serotonin and dopamine, which prolongs their duration in the synapse so that they can bind more readily to the receptors. The mechanism is not fully understood, but may be similar to other dopamine reuptake inhibitors where Sibutramine would cross the blood-brain barrier through diffusion. Dopamine is synthesized in the ventral tegmental area of the brain from tyrosine being synthesized into L-dopa by the enzyme Tyrosine 3-monooxygenase . L-Dopa is then synthesized into dopamine with the enzyme aromatic-L-amino-acid decarboxylase. Dopamine then travels to the prefrontal cortex, which is released into the synapse when the neuron is stimulated and fires. Sibutramine binds to the sodium-dependent dopamine transporter, preventing dopamine from re-entering the presynaptic neuron. The dopamine then binds to Dopamine D4 receptors on the postsynaptic membrane. The dopamine D4 receptor activates the Gi protein cascade, which inhibits adenylate cyclase. This prevents adenylate cyclase from catalyzing ATP into cAMP.

PW145194

Pw145194 View Pathway
drug action

Sibutramine Drug Metabolism Action Pathway

Homo sapiens

PW176231

Pw176231 View Pathway
metabolic

Sibutramine Predicted Metabolism Pathway

Homo sapiens
Metabolites of Sibutramine are predicted with biotransformer.

PW064707

Pw064707 View Pathway
signaling

Sigma B Activation

Bacteria

PW146361

Pw146361 View Pathway
drug action

Silanol Drug Metabolism Action Pathway

Homo sapiens

PW126170

Pw126170 View Pathway
drug action

Sildenafil Action Pathway

Homo sapiens
Sildenafil is a phosphodiesterase-5 inhibitor used for the treatment of erectile dysfunction. Sexual stimulation causes the release of nitric oxide (NO) from nerves and endothelial cells into the penis. NO activates the enzyme guanylate cyclase.2 The activation of this enzyme is followed by the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP), activating a cascade of protein kinase-dependent phosphorylation events in smooth muscles, ultimately resulting in the dephosphorylation of myosin light chains within smooth muscle. This activity causes the relaxation of smooth muscle within blood vessels, resulting in the desired vasodilatory effect. Phosphodiesterase-5 breaks down cGMP to GMP. Sildenafil inhibits phosphodiesterase-5, preventing the breakdown of cGMP. This increases the concentration of cGMP, increasing the vasodilation and improving blood flow leading to penile erection.

PW144334

Pw144334 View Pathway
drug action

Sildenafil Drug Metabolism Action Pathway

Homo sapiens

PW175936

Pw175936 View Pathway
metabolic

Sildenafil Predicted Metabolism Pathway

Homo sapiens
Sildenafil PIS1M1, Sildenafil PIS1M2, Sildenafil PIS2M1 are metabolites of Sildenafil predicted with biotransformer.

PW146253

Pw146253 View Pathway
drug action

Silicon dioxide Drug Metabolism Action Pathway

Homo sapiens

PW146576

Pw146576 View Pathway
drug action

Silicon Drug Metabolism Action Pathway

Homo sapiens